Showing results (301-310 of 3,351) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|April 3, 2023
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 studyToni K Choueiri, David F McDermott, Jaime Merchan, et al.
The Lancet. Oncology|May 4, 2023
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trialPeter Hillmen, Alexandra Pitchford, Adrian Bloor, et al.
The Lancet. Oncology|May 4, 2023
Single-arm studies involving patient-reported outcome data in oncology: a literature review on current practiceLimin Liu, Jungyeon Choi, Jammbe Z Musoro, et al.
The Lancet. Oncology|May 4, 2023
REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatmentEhsan Ghorani, Matteo Quartagno, Fiona Blackhall, et al.
The Lancet. Oncology|April 18, 2015
Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysisJonathon Torchia, Daniel Picard, Lucie Lafay-Cousin, et al.
The Lancet. Oncology|July 24, 2020
The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling studyCamille Maringe, James Spicer, Melanie Morris, et al.
The Lancet. Oncology|August 21, 2020
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trialVivek Subbiah, Ulrik Lassen, Elena Élez, et al.
The Lancet. Oncology|July 28, 2020
Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 studyDiane Goéré, Olivier Glehen, François Quenet, et al.
The Lancet. Oncology|April 15, 2021
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander M M Eggermont, Christian U Blank, Mario Mandalà, et al.
The Lancet. Oncology|April 15, 2021
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trialAndrew Bottomley, Corneel Coens, Justyna Mierzynska, et al.
Pageof 336